An Efficient In Vitro Transposition Method by a Transcriptionally Regulated Sleeping Beauty System Packaged into an Integration Defective Lentiviral Vector
January 12th, 2018
8.2K views
This protocol describes a method to achieve stable integration of a gene of interest into the human genome by the transcriptionally regulated Sleeping Beauty system. Preparation of the integration of defective lentiviral vectors, the in vitro transduction of human cells, and the molecular assay on transduced cells are reported.
Overview
This protocol describes a method to achieve stable integration of a gene of interest into the human genome using the transcriptionally regulated Sleeping Beauty system. The process includes the preparation of integration defective lentiviral vectors, in vitro transduction of human cells, and molecular assays on the transduced cells.
Key Study Components
Area of Science
- Gene therapy
- Cell biology
- Molecular biology
Background
- The Sleeping Beauty system is a transposon-based method for gene delivery.
- Integration of genes into the human genome is crucial for stable expression.
- Primary cells often resist traditional transfection methods.
- This method aims to improve gene integration efficiency in primary cells.
Purpose of Study
- To achieve stable gene integration in primary human cells.
- To utilize the Sleeping Beauty system for efficient gene delivery.
- To address challenges in gene therapy related to primary cell transfection.
Methods Used
- Preparation of integration defective lentiviral vectors.
- In vitro transduction of human primary keratinocytes.
- Molecular assays to assess gene integration.
- Use of trypsin for cell detachment prior to transduction.
Main Results
- Demonstration of stable gene integration in primary cells.
- Efficient delivery of genes using the Sleeping Beauty system.
- Successful transduction of human primary keratinocytes.
- Validation of molecular assays for assessing integration.
Conclusions
- The Sleeping Beauty system is effective for gene integration in primary cells.
- This method provides a reliable approach for gene therapy applications.
- Future studies can build on this protocol to explore other genes of interest.
Frequently Asked Questions
What is the Sleeping Beauty system?
The Sleeping Beauty system is a transposon-based method used for gene delivery and stable integration into the genome.
Why is stable gene integration important?
Stable gene integration allows for long-term expression of therapeutic genes in target cells, which is crucial for effective gene therapy.
What types of cells can be transduced using this method?
This method is designed for primary human cells, such as keratinocytes.
How does this method improve upon traditional transfection methods?
The Sleeping Beauty system is more efficient for primary cells that are often resistant to traditional transfection techniques.
What are the key steps in the protocol?
Key steps include preparing lentiviral vectors, transducing cells, and performing molecular assays to confirm integration.
Who demonstrated this procedure?
The procedure was demonstrated by Daniela Benati, a post-doc in the lab.
What is the significance of using integration defective lentiviral vectors?
Integration defective vectors help ensure that the transgene integrates into the genome without causing harmful effects associated with random integration.
Executive Industry Relevance
This method addresses a critical bottleneck in gene therapy: achieving stable transgene integration in primary human cells resistant to conventional transfection. By combining a transcriptionally regulated hyperactive Sleeping Beauty transposase with integration-defective lentiviral delivery, it enables tunable, efficient genomic modification in therapeutically relevant cell types. The approach supports preclinical de-risking by providing a reproducible platform for functional validation before clinical translation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables precise interrogation of gene function through stable, inducible genomic integration in primary cells.
- Operational Value: Overcomes transfection limitations in hard-to-transduce primary cells, expanding target validation scope.
Screening & Assay Development
- Scientific Value: Generates isogenic cell populations with defined transgene copy number for consistent phenotypic screening.
- Operational Value: Provides quantitative GFP-based readout via flow cytometry to assess integration efficiency across conditions.
Translational & Preclinical Research
- Scientific Value: Supports dose-dependent transgene expression tuning via doxycycline, enabling mechanistic de-risking of therapeutic constructs.
- Operational Value: Demonstrated 12% stable integration in primary keratinocytes, establishing a benchmark for preclinical efficacy assessment.
Pipeline & Workflow Integration
The method fits within the discovery-to-preclinical continuum, enabling stable cell line generation for target validation and lead optimization studies.
- Discovery Biology: Facilitates hypothesis testing by allowing controlled, long-term transgene expression in disease-relevant primary cells.
- Screening: Enables assay-ready cell populations with reproducible integration for compound screening campaigns.
- Analytics: Delivers quantifiable endpoints (GFP+ fraction, qPCR validation) to compare transduction conditions and optimize vector dosing.
- Translational Research: Bridges discovery and preclinical work by validating transgene performance in primary cells prior to in vivo studies.
- Enterprise Reuse: The IDLV-based delivery system can be adapted across multiple genes of interest and cell types, supporting platform scalability.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in transgene behavior through stable, inducible integration reducing epigenetic silencing risks.
- Operational Value: Standardized workflow using lentiviral transduction and doxycycline induction ensures reproducibility across labs and cell types.
- Strategic Value: Enables better go/no-go decisions by confirming functional integration before investing in downstream development.
- Portfolio Impact: Supports risk-adjusted prioritization of gene therapy candidates based on demonstrable primary cell engineering efficiency.
Implementation Considerations
- Requires expertise in lentiviral vector production, primary cell culture, and inducible expression systems.
- Dependent on access to HEK293T packaging cells, flow cytometry, and qPCR instrumentation for validation.
- Necessitates standardization of vector dosing and doxycycline concentration across cell types to ensure consistent transposition efficiency.
- Adaptation to diverse primary cell models may require optimization of transduction conditions and selection markers.
- Practical limitation: Efficiency depends on achieving sufficient co-delivery of transposase, modulator, and transposon vectors, necessitating titer optimization.
Biopharma FAQs
Why does inducible transposase expression matter for target validation?
Inducible control via the Tet-ON system allows precise timing of Sleeping Beauty transposase activity, reducing genomic instability risks during target validation in primary cells. This enables researchers to assess transgene function after integration without confounding effects from constitutive expression.
How does isolating the transposon donor vector support discovery pipeline goals?
Separating the T2 transposon carrying the gene of interest from transposase and modulator vectors enables independent titration of each component, optimizing integration efficiency. This modular approach supports systematic optimization in early discovery workflows.
What quantitative measurements confirm successful gene integration?
Flow cytometry quantifies GFP-positive cells as a direct readout of transposition efficiency, while qPCR validates transgene expression levels. Together, these provide orthogonal confirmation of stable genomic integration in transduced primary cells.
Why are replication requirements critical for cross-functional collaboration?
Reproducible integration rates (e.g., 12% in keratinocytes with doxycycline) establish a benchmark for comparing results across teams and cell types. Standardized protocols ensure that target validation data are transferable between discovery and preclinical groups.
What statistical analysis is needed before implementing this method in lead identification?
Analysis of variance across vector doses and doxycycline conditions is required to determine significant differences in integration efficiency. This statistical rigor ensures that observed effects are reliable before advancing candidates to preclinical studies.
Chapters in this video
0:05
Title
0:51
Transduction of Human Primary Keratinocytes
4:31
Cytofluorimetric Analysis of Transduced Primary Keratinocytes
6:24
Quantitative RT-PCR (qRT-PCR)
7:24
Results: Sleeping Beauty System Achieves Stable Integration of a GOI in the Human Genome
8:40
Conclusion
